This article is a correction to:
Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants
Hongjie Chen1Jiepeng Chen2Fuping Zhang3Yuanhui Li4Ronghua Wang2Qiang Zheng2Xu Zhang2Jun Zeng2Feng Xu5*
Yiguang Lin1,6,7*- 1Department of Traditional Chinese Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- 2Sungen Bioscience Co. Ltd., Shantou, China
- 3Department of Pharmacy, Shenyang Red Cross Hospital, Shenyang, China
- 4Guangzhou Center, Sinopharm Group Pharmaceutical Co., Ltd., Guangzhou, China
- 5Antithrombotic & Thrombolytic Innovative Drug Research Center, Shenyang Pharmaceutical University, Shenyang, China
- 6The Central Laboratory, First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
- 7School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia
A corrigendum on
Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants
by Chen, H., Chen, J., Zhang, F., Li, Y., Wang, R., Zheng, Q., Zhang, X., Zeng, J., Xu, F., and Lin, Y. (2022). Front. Cardiovasc. Med. 9:964977. doi: 10.3389/fcvm.2022.964977
In the published article, there was an error in Table 1 Baseline characteristics of the participants as published.
TABLE 1
Table 1. Baseline characteristics of the participants.
The corrected Table and correct format appear below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: nattokinase, atherosclerosis, hyperlipidaemia, anti-atherogenic drug, lipid lowering effect, retrospective study, lipid lowering agent, Nattokinase (NK)
Citation: Chen H, Chen J, Zhang F, Li Y, Wang R, Zheng Q, Zhang X, Zeng J, Xu F and Lin Y (2022) Corrigendum: Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Front. Cardiovasc. Med. 9:1076420. doi: 10.3389/fcvm.2022.1076420
Received: 21 October 2022; Accepted: 07 November 2022;
Published: 05 December 2022.
Edited and reviewed by: Baohui Xu, Stanford University, United States
Copyright © 2022 Chen, Chen, Zhang, Li, Wang, Zheng, Zhang, Zeng, Xu and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yiguang Lin, WWlndWFuZy5saW4mI3gwMDA0MDtob3RtYWlsLmNvbQ==; Feng Xu, MTM4NDAxNTc3MTImI3gwMDA0MDsxNjMuY29t